Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children

Thakur Satbir, PhD, Son Tran, Mohit Jain, PhD, Austin Lewis, Luis Murguia-Favela, MD, Faisal M Khan, PhD D (ABHI), Kevin J. Bielamowicz, MD, Olena Vaske, PhD, Victor A. Lewis, MD, Norman J. Lacayo, MD, Aru Narendran, MD PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-143381

Published: 2020

Journal Articles

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Chunfen Zhang, MD, Ritul Sharma, MSc., Thakur Satbir, PhD, Allison Cheney, Olena Vaske, PhD, Lauren Sanders, Jessica Boklan, MD, Victor A. Lewis, MD, Ronald Anderson, MDFRCPC, Olga Kovalchuk, MD, PhD, Norman J. Lacayo, MD, Aru Narendran, MD PhD, Kevin J. Bielamowicz, MD

Blood (2019) 134 (Supplement_1): 2633.

https://doi.org/10.1182/blood-2019-131444

Published: 2019

Journal Articles

Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL)

Son Tran, Mehul Gupta, Sunand Kannappan, Chunfen Zhang, MD, Aru Narendran, MD PhD

Blood (2019) 134 (Supplement_1): 3882.

https://doi.org/10.1182/blood-2019-132223

Published: 2019

Journal Articles

Targeting Oncogenic Polyamines in Refractory Pediatric Leukemias Using the Anti-Protozoan Drug Α-Difluoromethylornithine (DFMO) in Combination with GC7 and Aurothioglucose

Bradley Hofmann, MSc, Sunand Kannappan, Gupta Mehul, Chunfen Zhang, MD, Susan Chi, MD, Derek Hanson, MD, Ronald Anderson, MD FRCPC, Aru Narendran, MD PhD

Blood (2018) 132 (Supplement 1): 2725.

https://doi.org/10.1182/blood-2018-99-117229

Published: 2018

Journal Articles

In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia

Lucy Swift, PhD, Chunfen Zhang, MD, Ravi Shah, MD, Tanya Trippett, MD, Aru Narendran, MD PhD

Blood (2018) 132 (Supplement 1): 5207.

https://doi.org/10.1182/blood-2018-99-119438

Published: 2018

Journal Articles

Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine

Maneka Perinpanayagam, PhD, Anna Kovalchuk, Yibing Ruan, PhD, Sungmyung Kang, Aarthi Jayanthan, Olga Kovalchuk, Jessica Boklan, MD, Aru Narendran, MD PhD

Blood (2014) 124 (21): 983.

https://doi.org/10.1182/blood.V124.21.983.983

Published: 2014

Journal Articles

I n Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib

Aarthi Jayanthan, Yibing Ruan, PhD, Meaghan Hagerty, Ravi Shah, Tony Truong, MD, Victor A. Lewis, MD, Jessica Boklan, MD, Tanya Trippett, MD, Lia Gore, MD, Aru Narendran, MD, PhD

Blood (2013) 122 (21): 2673.

https://doi.org/10.1182/blood.V122.21.2673.2673

Published: 2013

Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD

Blood (2013) 122 (21): 2680.

https://doi.org/10.1182/blood.V122.21.2680.2680

Published: 2013

Journal Articles

Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia

Aarthi Jayanthan, Todd Cooper, DO, Sandra E. Dunn, PhD, Victor A. Lewis, MD, Aru Narendran, MD, PhD

Blood (2012) 120 (21): 3573.

https://doi.org/10.1182/blood.V120.21.3573.3573

Published: 2012

Journal Articles

Preclinical Evaluation of Oncolytic Reovirus in Targeted Therapeutics for High-Risk Pediatric Leukemia

Matthew F. Clarkson, Aru Narendran, MD, PhD, Randal N. Johnston, PhD

Blood (2012) 120 (21): 3571.

https://doi.org/10.1182/blood.V120.21.3571.3571

Published: 2012

Journal Articles

YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia

Amina Kariminia, PhD, Sabine M Ivison, PhD, Vivian Leung, Sandra E. Dunn, PhD, Aru Narendran, MD, PhD, Kirk R. Schultz, MD

Blood (2012) 120 (21): 1468.

https://doi.org/10.1182/blood.V120.21.1468.1468

Published: 2012

Journal Articles

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Lia Gore, MD, Margaret E. Macy, M.D., Francoise Mechinaud, MD, Aru Narendran, MD, PhD, Frank Alvaro, MD, Carola A.S. Arndt, MD, Phillip Barnette, MD, Jessica Boklan, MD, Todd Cooper, DO, Laura Martin, MD, W Tcheng, MD, Peter Tarassoff, MD, Mark M Jones, MD, Soheil Meshinchi, MD, PhD, Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 1517.

https://doi.org/10.1182/blood.V120.21.1517.1517

Published: 2012

Journal Articles

Preclinical Studies of Cytotoxicity, Drug Synergy and Biological Correlates of Clofarabine Against Infant Leukemia Cells

Aarthi Jayanthan, Anjali Singh, Victor A Lewis, MD, Aru Narendran, MD, PhD

Blood (2010) 116 (21): 4342.

https://doi.org/10.1182/blood.V116.21.4342.4342

Published: 2010

Journal Articles

Studies on GM-CSF Induced Signaling and Cell Growth in JMML: An Experimental Model To Identify Mechanism Directed Targeted Therapeutics.

Yu Ding, MD, Bijan Teja, Chris Blackmore, Sumita Dingwa, Eva Ujack, Christopher Brown, MD, Aru Narendran, MD, PhD

Blood (2005) 106 (11): 2765.

https://doi.org/10.1182/blood.V106.11.2765.2765

Published: 2005

Journal Articles

In Vitro Growth Regulation and the Identification of Potential Signaling Pathways in T (4; 11), Pediatric Pre-B Acute Lymphoblastic Leukemia (ALL).

Aru Narendran, MD, PhD, Bijan Tijan, Lucas Coppes, Farrah Rhemtulah, Ron Anderson

Blood (2004) 104 (11): 1896.

https://doi.org/10.1182/blood.V104.11.1896.1896

Published: 2004

NARROW

A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL)

Targeting Oncogenic Polyamines in Refractory Pediatric Leukemias Using the Anti-Protozoan Drug Α-Difluoromethylornithine (DFMO) in Combination with GC7 and Aurothioglucose

In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia

Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine

I n Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia

Preclinical Evaluation of Oncolytic Reovirus in Targeted Therapeutics for High-Risk Pediatric Leukemia

YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Preclinical Studies of Cytotoxicity, Drug Synergy and Biological Correlates of Clofarabine Against Infant Leukemia Cells

Studies on GM-CSF Induced Signaling and Cell Growth in JMML: An Experimental Model To Identify Mechanism Directed Targeted Therapeutics.

In Vitro Growth Regulation and the Identification of Potential Signaling Pathways in T (4; 11), Pediatric Pre-B Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only